

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LAUTT ET AL. Examiner: S. JAVANMARD  
Serial No.: 10/502,119 Group Art Unit: 1617  
Filed: JANUARY 12, 2005 Docket No.: 14430.6USWO  
Confirmation No.: 3382 Customer No.: 23552  
Title: USE OF PHOSPHODIESTERASE ANTAGONISTS TO TREAT  
INSULIN RESISTANCE

---

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is being submitted in response to the Restriction Requirement mailed January 3, 2008. Without acquiescing to the statements made therein, Applicants hereby elect the claims of Group III (claims 22, 48, 50, 52, 54, 56, 58, 60, 62 and 64) for prosecution in the instant application. In addition, the Examiner has required an election of a species. To fulfill the election of species requirement, Applicants elect tadalafil as the phosphodiesterase antagonist.

Applicants reserve the right to file one or more divisional applications on non-elected subject matter.

Examination on the merits is respectfully requested.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: 1/31/2008

  
\_\_\_\_\_  
Brian R. Dorn, Ph.D.  
Reg. No. 57,395

23552

PATENT TRADEMARK OFFICE